News

Catalent has announced a significant corporate transformation aimed at overhauling its manufacturing operations after a year of major industry shifts.

Alphamab Oncology secures regulatory approval to commence a pivotal Phase III clinical study of the innovative HER2-targeting ADC JSKN003 for advanced colorectal cancer in China, marking a major milestone in Asia's oncology drug development landscape.

Innovent Biologics and Takeda Pharmaceutical have announced a transformative $11.4 billion global oncology partnership for the development and commercialization of advanced cancer therapies.

Abolis Biotechnologies and EUROAPI launch a major partnership under the IPCEI Med4Cure program to restore EU production of corticosteroids and secure critical supply chains.

Chinese biotech Biokin receives a $250 million milestone payment from BMS, marking the largest ADC deal to date, and drives accelerated global regulatory progress for its innovative cancer drug.

INEOS warns that European pharmaceutical supply chains and manufacturing capacity are imperiled by high energy costs, carbon taxes, and lack of regulatory support, calling for urgent EU intervention.

The FDA has restricted updated COVID-19 vaccine approvals to seniors and certain high-risk individuals under 65, ending routine access for healthy children and pregnant women and raising operational, regulatory, and supply chain concerns across the pharma sector.

Innovent Biologics and Takeda have announced a sweeping $11.4 billion oncology alliance focused on global co-development and commercialization of immuno-oncology and ADC drug candidates.

Cambrex announces a major $120 million investment to expand active pharmaceutical ingredient (API) manufacturing capacity in the U.S., targeting enhanced supply chain resilience.

EVOQ Therapeutics has entered into a Collaboration and Licence Agreement with Sanofi. The partnership focuses on advancing EVOQ’s proprietary NanoDisc technology, which aims to restore the body’s natural immune tolerance mechanisms.